LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

25.44 -8.62

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.95

Максимум

25.99

Ключови измерители
By Trading Economics
Приходи	23M 7.4M
Продажби	18M 99M
EPS	0.06
Марж на печалбата	7.468
Служители	342
EBITDA	23M 11M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+25.89% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	756M 3.2B
Предишно отваряне	34.06
Предишно затваряне	25.44

Настроения в новините

By Acuity

50%

159 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.02.2026 г., 17:37 ч. UTC

Придобивния, сливания и поглъщания

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20.02.2026 г., 16:18 ч. UTC

Значими двигатели на пазара

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20.02.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20.02.2026 г., 22:12 ч. UTC

Печалби

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.02.2026 г., 21:23 ч. UTC

Печалби

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20.02.2026 г., 21:20 ч. UTC

Пазарно говорене

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20.02.2026 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20.02.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20.02.2026 г., 20:17 ч. UTC

Пазарно говорене

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20.02.2026 г., 20:11 ч. UTC

Пазарно говорене

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20.02.2026 г., 19:59 ч. UTC

Пазарно говорене

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20.02.2026 г., 19:58 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20.02.2026 г., 19:49 ч. UTC

Пазарно говорене

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20.02.2026 г., 19:09 ч. UTC

Пазарно говорене

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20.02.2026 г., 19:00 ч. UTC

Пазарно говорене

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20.02.2026 г., 18:28 ч. UTC

Пазарно говорене

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20.02.2026 г., 18:20 ч. UTC

Пазарно говорене

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20.02.2026 г., 18:05 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

20.02.2026 г., 18:04 ч. UTC

Пазарно говорене

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20.02.2026 г., 17:38 ч. UTC

Пазарно говорене

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20.02.2026 г., 17:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.02.2026 г., 17:24 ч. UTC

Пазарно говорене

Correction to Treasury Yields Fall Market Talk

20.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

20.02.2026 г., 16:53 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

20.02.2026 г., 16:53 ч. UTC

Пазарно говорене

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20.02.2026 г., 16:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.02.2026 г., 16:45 ч. UTC

Пазарно говорене

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20.02.2026 г., 16:40 ч. UTC

Пазарно говорене

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

25.89% нагоре

12-месечна прогноза

Среден 32 USD 25.89%

Висок 37 USD

Нисък 30 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

159 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.